Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Impact of pretreatment with Acetylsalicylic acid on the severity of a first Myocardial Infarction
Session:
Posters 4 - Écran 5 - Doença Coronária
Speaker:
Ana Rita Moura
Congress:
CPC 2019
Topic:
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
Theme:
13. Acute Coronary Syndromes
Subtheme:
13.2 Acute Coronary Syndromes – Epidemiology, Prognosis, Outcome
Session Type:
Posters
FP Number:
---
Authors:
Ana Rita Moura; Mariana Saraiva; Nuno Craveiro; Maria João Matos Vieira; Kevin Domingues; Vitor Paulo Martins; Margarida Leal
Abstract
<p><strong>Introduction</strong>: Guidelines on the use of acetylsalicylic acid (ASA) for primary prevention of Cardiovascular Disease (CVD) are conflicting and a reflection of no robust evidence accounting for unequivocal favourable benefit-to-risk balance of its use. An eventual advantage of AAS in reducing the severity and prognostic impact of a first episode of Acute Myocardial Infarction (AMI) could be seen has an additional argument for the use of ASA in primary prevention. The present study aimed to evaluate the influence of ASA on the presentation, severity and in-hospital prognosis of AMI in patients without history of CVD.</p> <p><strong>Methods</strong>: Retrospective study based on the analysis of patients without previous evidence of CVD that were diagnosed with type 1 AMI in a district hospital between January 2016 and December 2017. The analysis was dichotomized according to whether or not patients were taking ASA previous to the event. The following endpoints were evaluated: type of AMI, angor refractoriness, maximal troponin, ejection fraction (EF), coronary grade flow (TIMI score), arrhythmic and mechanical complications, and in-hospital death.</p> <p><strong>Results: </strong>The study was accomplished for a total of 150 patients with a mean age of 71.6±9.5 years, of which 71.3% were male. The group of patients that was receiving ASA (16.7%) was significantly older and had a higher prevalence of hypertension (96.0% vs 72.5%, p=0.01), and diabetes (68.0% vs. 29.2%, p <0.001). Regarding the endpoints studied, in the group of patients taking the drug there was a lower prevalence of AMI with ST segment elevation (24.0% vs. 36.7%, p=0.26), lower prevalence of refractory angor (4.0% vs. 11.7% , p=0.46), a lower troponin elevation (7065 vs. 33412.0, p=0.78), a higher median EF (55.2±3.5 vs. 47.5±6.3, p=0.52), less cases with TIMI score 0 or 1 (40.0% vs. 60.0%; p=0.79), lower complication rates (4.0% vs. 7.6%, p=1.00) and less in-hospital death (0% vs. 1.7%). However, none of the observations was associated with statistical significance.</p> <p><strong>Conclusions</strong>: The present study revealed that, although statistical significance was not reached, prior use of ASA to a first AMI was associated with a better profile of different parameters reflecting the extent and severity of the event. Adequately powered trials are needed to evaluate the relevance of these findings.</p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site